Loading...
Loading...
• Dell Inc.
DELL reported Q1 EPS of $0.55, higher than the Zacks Consensus Estimate of $0.43 per share. Revenue for the quarter edged up 1% year-over-year to $15.02 billion, falling short of the Zacks Consensus Estimate of $15.457 billion
• Share prices of US listed Allied Irish Banks, PLC.
AIB rose 13.33% to close at $3.06 after the banking company unveiled a new structure and top management team
• Leerink Swann initiated coverage on shares of Anthera Pharmaceuticals, Inc.
ANTH with an "Outperform" rating and a valuation call of $12 to $14 per share
• Share prices of elong, Inc.
LONG increased 56.72% on news that China‘s Tencent Holdings has bought a 16% stake in the company for $84.4 million
• Shares of FairPoint Communications, Inc.
FRP fell more than 40% to close at $9.59. Although the company posted first quarter profits, its revenues were flat compared to the prior year
Loading...
Loading...
• Analysts at Madison Williams initiated coverage on Linn Energy, LLC
LINE with a “Buy” rating and a target price of $45.00
• Analysts at Goldman Sachs
GS initiated coverage on MAKO Surgical
MAKO with a “Buy” rating
• Analysts at Boenning & Scattergood initiated coverage on Nektar Therapeutics
NKTR with an “Outperform” rating and a target price of $15.00
• Analysts at Oppenheimer analysts initiated coverage on Oncolytics Biotech, Inc.
ONCY setting a “perform” rating
• Analysts at ThinkEquity initiated coverage on Optimer Pharmaceuticals, Inc.
OPTR with a “Buy” rating and a target price of $18.00
ALLIED IRISH BK (AIB): Free Stock Analysis Report
ANTHERA PHARMA (ANTH): Free Stock Analysis Report
DELL INC (DELL): Free Stock Analysis Report
GOLDMAN SACHS (GS): Free Stock Analysis Report
LINN ENERGY LLC (LINE): Free Stock Analysis Report
ELONG INC-ADR (LONG): Free Stock Analysis Report
MAKO SURGICAL (MAKO): Free Stock Analysis Report
NEKTAR THERAP (NKTR): Free Stock Analysis Report
ONCOLYTICS BIO (ONCY): Free Stock Analysis Report
OPTIMER PHARMAC (OPTR): Free Stock Analysis Report
Zacks Investment Research
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in